1 results match your criteria: "Service de Pharmacologie Clinique Centre antipoison et de Toxicovigilance[Affiliation]"
Cannabinoid hyperemesis syndrome in two French emergency departments: a prospective cohort.
Fundam Clin Pharmacol
February 2021
APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Hôpital Sainte Marguerite, Service de Pharmacologie Clinique Centre antipoison et de Toxicovigilance, Aix Marseille Univ, Marseille, France.
Chronic cannabis use can be associated with uncontrollable vomiting and abdominal pain. Diagnostic criteria for cannabinoid hyperemesis syndrome (CHS) were defined in 2012 by Simonetto et al. The objectives of this study were to describe the prevalence of CHS, the patients' epidemiological characteristics, and to show the difficulties encountered in caring for these patients in emergency departments, the extent of health care and an unsuitable follow-up in general practices.
View Article and Find Full Text PDF